The Role of Antidepressants or Antipsychotics in Preventing Psychosis

St. Luke's-Roosevelt Hospital Center

Status

Withdrawn

Conditions

Psychotic Disorder

Treatments

Drug: Antidepressant

Drug: Antipsychotic

Study type

Interventional

Funder types

Other

Identifiers

NCT01724372

12-094

Details and patient eligibility

About

This is a randomized, controlled pilot study comparing the antidepressant fluoxetine with the second generation antipsychotic aripiprazole in approximately 10 subjects aged 12-25 at risk for developing psychosis.

Our primary hypotheses are that compared to aripiprazole, fluoxetine will be better tolerated and will lead to greater improvement in symptoms at the end of 6 months of treatment.

Sex

All

Ages

12 to 25 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

12-25 years of age (inclusive)
Able to understand and speak English
Have at least one sub-threshold positive psychotic symptom that is moderate, moderately severe, or severe

Exclusion criteria

Lifetime diagnosis of an Axis I psychotic disorder: schizophreniform disorder; schizophrenia; schizoaffective disorder; bipolar disorder; or major depression with psychotic features
Current psychosis
Current diagnosis of Major Depressive Disorder, single episode or recurrent, severe without psychotic features
Lifetime diagnosis of substance abuse or dependence (excluding nicotine)
Current stimulant treatment
Any significant medical condition that contra-indicates treatment with either aripiprazole or fluoxetine, including history of neurological, neuroendocrine or other medical condition known to affect the brain
Estimated intelligence quotient < 70